Alkem Laboratories has announced an interim dividend of ₹43 per equity share with a face value of ₹2 each for the financial year 2025–26. The dividend declaration comes in accordance with Regulation 43 read with Regulation 30 of the SEBI (LODR) Regulations, reinforcing the company’s continued focus on shareholder returns.
The interim dividend announcement was made alongside the company’s Q3 financial results, where Alkem reported steady year-on-year growth in revenue and profitability despite margin pressures.
For the third quarter, net profit rose 1.6% YoY to ₹636 crore compared to ₹625.8 crore in the corresponding quarter last year. Revenue from operations increased 10.7% YoY to ₹3,737 crore, up from ₹3,374 crore in the year-ago period, reflecting healthy demand across domestic and international markets.
Operating performance remained stable, with EBITDA growing 9% YoY to ₹826.8 crore versus ₹759.2 crore in Q3 of the previous fiscal. However, EBITDA margin slightly moderated to 22.1% compared to 22.5% last year, indicating mild cost pressures during the quarter.
